PSMA-PET/CT在前列腺癌原发与继发分期中的组织病理学验证诊断准确性及对临床管理的影响:系统评价与Meta分析
该系统评价与Meta分析基于PRISMA指南检索Medline、Embase、PubMed和Cochrane Library数据库,评估PSMA PET/CT在局限性、淋巴结转移性和生化复发前列腺癌中的诊断准确性及对临床管理的影响。结果显示局限性前列腺癌灵敏度71.0%、特异度92.0%,淋巴结转移灵敏度57.0%、特异度96.0%,生化复发灵敏度84.0%、特异度97.0%;原发和复发患者管理改变合并比例分别为28.0%和54.0%。
要点
- PSMA PET/CT对局限性前列腺癌灵敏度71.0%、特异度92.0%(N=10;n=404例)。
- 淋巴结转移灵敏度57.0%、特异度96.0%(N=36;n=3659例),生化复发灵敏度84.0%、特异度97.0%(N=9;n=818例)。
- 原发和复发前列腺癌管理改变合并比例分别为28.0%和54.0%。
核心结论
- PSMA PET/CT在局限性和淋巴结转移性疾病中显示中等灵敏度和高特异度,在生化复发患者中准确性高。
- PSMA PET/CT对前列腺癌患者的临床管理有较大影响。
- 这是最广泛且首个纳入三个前列腺癌亚组、分别报告组织学验证诊断准确性和原发与复发疾病管理改变的系统评价。
研究设计与样本
- 系统评价与Meta分析,基于PRISMA指南检索Medline、Embase、PubMed和Cochrane Library数据库。
- 纳入报告PSMA PET/CT诊断准确性和临床管理的研究,采用随机效应模型进行统计分析,并用Meta回归探索观察到的异质性。
主要发现
- 局限性前列腺癌:灵敏度71.0%(95%CI:58.0,81.0),特异度92.0%(95%CI:86.0,96.0)(N=10;n=404例)。
- 淋巴结转移:灵敏度57.0%(95%CI:49.0,64.0),特异度96.0%(95%CI:95.0,97.0)(N=36;n=3659例)。
- 生化复发:灵敏度84.0%(95%CI:74.0,90.0),特异度97.0%(95%CI:88.0,99.0)(N=9;n=818例)。
- 原发前列腺癌管理改变合并比例28.0%(95%CI:23.0,34.0)(N=16;n=1099例)。
- 复发前列腺癌管理改变合并比例54.0%(95%CI:50.0,58.0)(N=40;n=5398例)。
关键数值与推荐
- 局限性前列腺癌灵敏度71.0%(95%CI:58.0,81.0)、特异度92.0%(95%CI:86.0,96.0)(N=10;n=404例)。
- 淋巴结转移灵敏度57.0%(95%CI:49.0,64.0)、特异度96.0%(95%CI:95.0,97.0)(N=36;n=3659例)。
- 生化复发灵敏度84.0%(95%CI:74.0,90.0)、特异度97.0%(95%CI:88.0,99.0)(N=9;n=818例)。
- 原发前列腺癌管理改变合并比例28.0%(95%CI:23.0,34.0)(N=16;n=1099例)。
- 复发前列腺癌管理改变合并比例54.0%(95%CI:50.0,58.0)(N=40;n=5398例)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA) is a highly expressed protein in prostate cancer (PCa) and has become an increasingly popular target for molecular imaging in recent years. PSMA based positron-emission-tomography/computed tomography (PET/CT) is a well characterised hybrid imaging modality that combines the high sensitivity of PET with the high spatial resolution of CT imaging. The combination of these two imaging modalities provides an accurate tool for detecting and managing PCa. Several diagnostic accuracy and clinical management studies investigating the role of PSMA PET/CT in PCa have been published recently. This study aimed to perform an updated systematic review and meta-analysis to evaluate the diagnostic performance of PSMA PET/CT in localised, lymph node metastatic (LNM) and recurrent PCa patients and assess its impact on the clinical management of primary and recurrent PCa. Using Medline, Embase, PubMed and Cochrane Library databases, studies reporting the diagnostic accuracy and clinical management of PSMA PET/CT were analysed based on the PRISMA guidelines. Statistical analyses were conducted using random-effects models, and meta-regression explored observed heterogeneity. Results indicate that the sensitivity and specificity of PSMA PET/CT for localised PCa were 71.0% (95% confidence interval (CI): 58.0, 81.0) and 92.0% (95% CI: 86.0, 96.0), respectively (N = 10; n = 404 patients). Sensitivity and specificity in LNM were 57.0% (95% CI: 49.0, 64.0) and 96.0% (95% CI: 95.0, 97.0) (N = 36; n = 3,659 patients). For patients with biochemical recurrence (BCR), sensitivity was 84.0% (95% CI: 74.0, 90.0), and specificity was 97.0% (95% CI: 88.0, 99.0) (N = 9; n = 818 patients). The pooled proportion of management changes in primary (N = 16; n = 1,099 patients) and recurrent (N = 40; n = 5,398 patients) PCa was 28.0% (95% CI: 23.0, 34.0) and 54.0% (95% CI: 50.0, 58.0), respectively. In conclusion, PSMA PET/CT shows moderate sensitivity and high specificity in localised and LNM disease, while the accuracy in BCR patients was high. PSMA PET/CT also had a large impact on the clinical management of PCa patients. This is the most extensive and first systematic review to include three subgroups of PCa with histologically verified diagnostic accuracy and clinical management change reported separately in primary and recurrent disease settings.
引用
- Jeet V, Parkinson B, Song R, et al. Histopathologically Validated Diagnostic Accuracy of PSMA-PET/CT in the Primary and Secondary Staging of Prostate Cancer and the Impact of PSMA-PET/CT on Clinical Management: A Systematic Review and Meta-analysis. Semin Nucl Med. 2023. PMID: 37005145. doi:10.1053/j.semnuclmed.2023.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。